- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.01. | Kailera reports Zepbound-rivaling weight loss in phase 2 obesity trial | ||
| 13.01. | JPM25: Regeneron, Illumina and more back Truveta for 10M genome sequencing project | ||
| 13.01. | JPM25: Eli Lilly strikes $2.5B Scorpion buyout in twist to breast cancer tale | ||
| 13.01. | JPM25: Guardant Health posts 31% sales gain as cancer blood tests expand | ||
| 13.01. | Telix continues shopping spree with $45M purchase of ImaginAb's preclinical drugs, facility | ||
| 13.01. | Blueprint ends work on clinical-stage CDK2 inhibitor but pushes on in breast cancer | ||
| 13.01. | Epigenetic biotech raises bumper round to the Tune of $175M to fund entry into clinic | ||
| 11.01. | Obesity-focused Metsera files IPO just nine months after emerging | ||
| 10.01. | IGM, Y-mAbs, Passage Bio and more telegraph staff cuts amid restructuring spree | ||
| 10.01. | 4DMT tosses 2 programs, halts funds for 3 others as it zeroes in on latest-stage clinical gene therapy | ||
| 10.01. | Kardigan launches with cozy $300M series A and collection of late-stage cardio assets | ||
| 10.01. | Saluda Medical toasts $100M fundraising to pep up sales of its closed-loop neurostimulator | ||
| 10.01. | AbbVie takes $3.5B hit after emraclidine's phase 2 flop in schizophrenia | ||
| 10.01. | Eli Lilly, Andreessen Horowitz link up on $500M biotech venture fund | ||
| 10.01. | Novo Holdings-backed Windward generates $200M series A, inks $970M biobucks deal for clinical antibody | ||
| 10.01. | Biotech creator and China's Keymed launch antibody company with $180M series A | ||
| 10.01. | Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar's midphase prospect | ||
| 10.01. | Pfizer's PD-1 prospect beats age-old incumbent in phase 3 bladder cancer trial | ||
| 10.01. | Bausch + Lomb pens $485M-plus biobucks pact with City Tx for RNAi eye disease work | ||
| 10.01. | Repare cans plans for phase 3 cancer combo trial in latest money-saving move | ||
| 10.01. | Intellia, citing 'challenging market environment,' lays off 27% of staff as it takes ax to pipeline | ||
| 08.01. | Sana's cell therapy may be 'transformative cure' for type 1 diabetes: analysts | ||
| 08.01. | Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes | ||
| 08.01. | LB Pharma's twist on old Sanofi drug passes schizophrenia test, teeing up phase 3 push | ||
| 08.01. | Galapagos splits in two, laying off 40% of staff, shrinking pipeline and ending Gilead partnership |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
